Cagrilintide: uses, dosing & the facts

A long-acting synthetic peptide that mimics amylin, a hormone co-secreted with insulin. Acts as a dual agonist for amylin and calcitonin receptors. Often studied in combination with Semaglutide (CagriSema) or Retatrutide (CagriReta) for enhanced weight loss. This is an evidence-graded reference — what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.

By OptiPin Editorial·Last updated July 2026

Status

Research use only · not FDA-approved. Reported dosing below reflects community-discussed patterns, presented for information only — not a dose recommendation. For the US regulatory picture on research peptides, see the 2026 FDA compounding status.

Class

Fat loss

Used for

Obesity treatment

Half-life

Extended half-life v…

Status

Research use only

TL;DR

• Cagrilintide — Fat loss. A long-acting synthetic peptide that mimics amylin, a hormone co-secreted with insulin.
• Commonly used for obesity treatment, type 2 diabetes management, enhanced satiety and appetite reduction.
• Half-life: Extended half-life via fatty acid acylation.
• Status: Research use only · not FDA-approved — an educational reference, not a dose protocol or sourcing advice.

What Cagrilintide is

What Cagrilintide is used for

• Obesity treatment
• Type 2 diabetes management
• Enhanced satiety and appetite reduction
• Slower gastric emptying
• Blood glucose stabilization
• Combination therapy with GLP-1 agonists

These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.

Typical reported dosing

Injectable

Weeks 1-4: 0.25mg (10 units) once weekly. Weeks 5-8: 0.5mg (20 units) weekly. Weeks 9-12: 1.0mg (40 units) weekly. Weeks 13-16: 1.7mg (68 units) weekly. Subcutaneous injection.

Presented as commonly-reported patterns for information only — not a dose recommendation. Cagrilintide dosing is a decision for a qualified clinician.

Reconstitution

Reconstitute 5mg vial with 2mL BAC water. 0.25mg = 10 units, 0.5mg = 20 units, 1.0mg = 40 units, 1.7mg = 68 units. The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the reconstitution calculator.

Half-life & cycling

Half-life: Extended half-life via fatty acid acylation. Half-life drives dosing frequency and how quickly the compound clears — see it plotted on the half-life visualizer.

Cycling

Continuous use. Doses escalated every 4 weeks to reduce side effects like nausea.

Side effects & warnings

• Nausea
• Gastrointestinal side effects
• Appetite suppression
• Expected similar to GLP-1 medications

Research use only. Often used in combination therapy with GLP-1 agonists for enhanced weight loss and glycemic control. Gradual dose escalation recommended to minimize side effects.

Not a prescription, a dose, or a sourcing guide. Cagrilintide is a research compound; safety and efficacy in humans are not fully established, and research-grade material has no guarantee of purity, sterility, or stated strength. OptiPin is a tracking tool and does not recommend using research chemicals. Discuss any peptide with a qualified clinician.

Tracking Cagrilintide in OptiPin

If you're tracking a Cagrilintide protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math — all on-device, no account.

Track it properly

Log doses, outcomes & vials in OptiPin

Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math — all on-device.

Download on the App Store

FAQ

What is Cagrilintide?

What is Cagrilintide used for?

Commonly discussed uses include: obesity treatment, type 2 diabetes management, enhanced satiety and appetite reduction, slower gastric emptying, blood glucose stabilization, combination therapy with glp-1 agonists. These are reported uses, not proven outcomes or a recommendation.

How is Cagrilintide dosed?

Commonly reported dosing: Injectable — Weeks 1-4: 0.25mg (10 units) once weekly. Weeks 5-8: 0.5mg (20 units) weekly. Weeks 9-12: 1.0mg (40 units) weekly. Weeks 13-16: 1.7mg (68 units) weekly. Subcutaneous injection.. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation — Cagrilintide is not an approved medicine and dosing should involve a qualified clinician.

How do you reconstitute Cagrilintide?

Reconstitute 5mg vial with 2mL BAC water. 0.25mg = 10 units, 0.5mg = 20 units, 1.0mg = 40 units, 1.7mg = 68 units. On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.

What is Cagrilintide's half-life?

Extended half-life via fatty acid acylation. Half-life shapes how often it is dosed and how quickly it clears.

What are Cagrilintide's side effects?

Reported effects include: nausea, gastrointestinal side effects, appetite suppression, expected similar to glp-1 medications. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.

Educational only, not medical advice. Cagrilintide is a research compound and is not an approved medicine for the uses described. OptiPin is a tracking tool and does not provide dosing or treatment advice. Discuss any peptide with a qualified clinician.

Evidence & further reading

Search the peer-reviewed literature for Cagrilintide on PubMed (entry point to the primary evidence base, not a specific citation).
Cagrilintide on ClinicalTrials.gov — registered human trials, if any.
US FDA / 503A compounding status of research peptides (2026).
OptiPin peptides guide — categories, evidence grading, and how to run a protocol honestly.

Frag 176-191 · MOTS-C · SLU-PP-332 · Tesofensine · Tirzepatide (Mounjaro/Zepbound) · Reconstitution calculator · All peptides